Mucosal melanoma is rare, comprising only 1.4% of all melanomas in the United States. Yet it is associated with a worse prognosis compared to cutaneous melanoma due to aggressive biology and advanced stage at diagnosis with a reported 5-year survival rate of less than 30%. Although there are no established guidelines for the treatment of mucosal melanoma, immunotherapy has been increasingly used for the management of advanced mucosal melanoma.
Lee, Joanne Jee Yeon; Kearns, Donovan; Rodrigues, Medora; Babcock, Blake; Solomon, Naveenraj L. MD; Senthil, Maheswari MD; Reeves, Mark E. MD, PhD; Garberoglio, Carlos A. MD; and Namm, Jukes P. MD
"Factors Associated with Access to Immunotherapy and Its Impact on Survival in Mucosal Melanoma,"
Loma Linda University Student Journal: Vol. 3
, Article 6.
Available at: http://scholarsrepository.llu.edu/llu-student-journal/vol3/iss1/6